Anabolix8
Board Rep
- Joined
- Dec 25, 2024
- Messages
- 930
- Reaction score
- 508
24% Weight Loss: Retatrutide's Phase 3 Data BreakdownThe recent Phase 3 clinical trial data on Retatrutide has just set a new benchmark in obesity and metabolic medicine.
Over a 72-week period, participants in the highest-dose group lost up to 24.2% of their body weight — without surgery, crash dieting, or unsafe stimulants.
That’s not just fat loss — that’s systemic metabolic correction.
Watch the video above for a visual breakdown of the study data and the science behind Retatrutide’s game-changing performance.
Retatrutide is the first of its kind:
A triple hormone receptor agonist that activates:
- GLP-1 – reduces appetite and delays gastric emptying
- GIP – improves insulin sensitivity and supports fat metabolism
- Glucagon receptors – increases energy expenditure and promotes fat oxidation
This multi-pathway synergy offers results that go far beyond existing GLP-1s like semaglutide or tirzepatide.
24.2% average weight loss at 72 weeks (in the 12mg group)- Improved HbA1c, insulin sensitivity, and lipid markers
- High tolerability with manageable GI side effects
- Positive impact on cardiometabolic health
Retatrutide is more than a weight loss agent — it’s a metabolic tool with the potential to reshape how we treat:
- Obesity
- Insulin resistance
- Cardiovascular risk
- Inflammatory markers
As more long-term data rolls in, this could become the most powerful peptide in modern therapeutic use.
